| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
BF738735 targets phosphatidylinositol 4-kinase III beta (PI4KIIIβ) with an IC₅₀ of 5.7 nM. It displays approximately 200-fold selectivity over PI4KIIIα. BF738735 also targets OSBP and inhibits cholesterol shuttling to replication organelles. By inhibiting PI4KIIIβ, BF738735 disrupts the replication of enteroviruses, which require this enzyme for the formation of replication organelles. Its antiviral properties make it a valuable tool for studying viral replication and developing antiviral therapies.
|
|---|---|
| ln Vitro |
BF738735 (Compound 1) exhibits a substantial inhibitory effect on PI4KIIIβ activity in vitro, with an IC50 of 5.7 nM. PI4KIIIα is also harmed by BF738735, however not until 300 times greater concentrations (IC50 of 1.7 μM) are reached. Furthermore, BF738735's activity was examined using a panel of 150 cellular kinases, including 13 lipid kinases at a 10 μM dose. In vitro inhibition of PI4KIIIβ is unique to BF738735, as evidenced by inhibition rates for all kinases being less than 10%. With 50% effective doses ranging from 4 to 71 nM, BF738735 has broad-spectrum antiviral action and inhibits all enterovirus and rhinovirus species tested. All viruses examined were successfully suppressed by BF738735, with EC50 values ranging from 4 to 71 nM. Analyzed concurrently with EC50 and under identical culture circumstances for a duration of 3 to 4 days, BF738735 demonstrated lower cytotoxicity, with CC50 values varying between 11 and 65 μM, culminating in a notable selectivity index. Low BF738735 concentrations decreased luciferase levels to the GuaHCl treatment level, suggesting that BF738735 inhibits the replication of viral RNA. In this experiment, BF738735's EC50 of 77 nM is similar to the inhibition seen in a multicycle assay for coxsackievirus serotype B3 (CVB3) [1].
In vitro, BF738735 is a potent and selective PI4KIIIβ inhibitor with an IC₅₀ of 5.7 nM. It displays approximately 200-fold selectivity over PI4KIIIα. BF738735 displays antiviral properties and is a broad-spectrum enterovirus replication inhibitor. It targets OSBP and inhibits cholesterol shuttling to replication organelles. In cell-based assays, BF738735 treatment results in inhibition of enterovirus replication and disruption of viral membrane fusion. |
| ln Vivo |
Good plasma levels of antiviral medications were present in the samples, and BF738735 was well tolerated. At the 25 mg/kg dose, full inhibition was seen, while at the 5 mg/kg dose, some inhibition was noted [2].
In vivo, BF738735 has been studied for its antiviral activity against enteroviruses. As a PI4KIIIβ inhibitor, it disrupts viral replication and has potential for the treatment of enterovirus infections. However, detailed in vivo efficacy data are limited. The compound is primarily used as a research tool in in vitro studies of viral replication. Comprehensive in vivo studies are needed to fully characterize its therapeutic potential. |
| Enzyme Assay |
In vitro enzyme assays for BF738735 involve measuring its inhibition of PI4KIIIβ activity. The enzyme is incubated with varying concentrations of BF738735 in the presence of phosphatidylinositol and ATP. The phosphorylation of phosphatidylinositol is measured, and the IC₅₀ (5.7 nM) is calculated. Selectivity for PI4KIIIβ over PI4KIIIα is assessed using similar assays. These assays confirm the compound's mechanism as a potent and selective PI4KIIIβ inhibitor.
|
| Cell Assay |
In vitro cell-based assays for BF738735 evaluate its antiviral activity against enteroviruses. Cells infected with enteroviruses are treated with BF738735, and viral replication is measured by plaque assay or RT-PCR. The compound's effects on viral membrane fusion and replication organelle formation are assessed using microscopy and biochemical assays. These assays confirm the compound's functional activity as an antiviral agent.
|
| Animal Protocol |
In vivo animal experiments for BF738735 have not been extensively reported. The compound is primarily used as a research tool in in vitro studies of viral replication. For potential in vivo studies, BF738735 can be administered via oral or intraperitoneal routes in animal models of enterovirus infection. Viral load, disease severity, and survival would be assessed. Comprehensive in vivo studies are needed.
|
| ADME/Pharmacokinetics |
Pharmacokinetic (PK) data for BF738735 are limited. The compound has a molecular weight of 426.46 g/mol and is soluble in DMSO (90 mg/mL). It should be stored as a powder at -20°C for 3 years or in solvent at -80°C for 6 months. The compound's metabolic stability, half-life, and bioavailability have not been fully characterized. Comprehensive ADME studies are needed.
|
| Toxicity/Toxicokinetics |
The toxicity profile of BF738735 has not been extensively characterized. As a research compound, it should be handled with appropriate safety precautions. The compound is for research use only and is not intended for human or veterinary use. Comprehensive toxicological studies are needed to fully characterize the safety profile of BF738735.
|
| References | |
| Additional Infomation |
BF738735 is a potent and selective PI4KIIIβ inhibitor with an IC₅₀ of 5.7 nM. It displays antiviral properties and is a broad-spectrum enterovirus replication inhibitor. BF738735 targets OSBP and inhibits cholesterol shuttling. It disrupts viral membrane fusion. BF738735 has a molecular formula of C₂₁H₁₉FN₄O₃S. It is a research tool and has not progressed to clinical trials.
|
| Molecular Formula |
C21H19FN4O3S
|
|---|---|
| Molecular Weight |
426.463966608047
|
| Exact Mass |
426.116
|
| CAS # |
1436383-95-7
|
| PubChem CID |
135742054
|
| Appearance |
White to off-white solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Index of Refraction |
1.672
|
| LogP |
2.68
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
30
|
| Complexity |
690
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC1=C(N2C=CN=C(C2=N1)NCC3=CC(=CC=C3)S(=O)(=O)C)C4=CC(=C(C=C4)O)F
|
| InChi Key |
IMHZCCZYPHJVMS-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C21H19FN4O3S/c1-13-19(15-6-7-18(27)17(22)11-15)26-9-8-23-20(21(26)25-13)24-12-14-4-3-5-16(10-14)30(2,28)29/h3-11,27H,12H2,1-2H3,(H,23,24)
|
| Chemical Name |
2-fluoro-4-[2-methyl-8-[(3-methylsulfonylphenyl)methylamino]imidazo[1,2-a]pyrazin-3-yl]phenol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~125 mg/mL (~293.11 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (4.88 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (4.88 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (4.88 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3449 mL | 11.7244 mL | 23.4489 mL | |
| 5 mM | 0.4690 mL | 2.3449 mL | 4.6898 mL | |
| 10 mM | 0.2345 mL | 1.1724 mL | 2.3449 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
